Kymera Therapeutics
Develops oral protein degraders for immunology and partnered oncology programs.
$118.15
After-hours close+0.07 (+0.06%)
At close$118.08(−1.79%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 126.10%Insiders 3.38%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 82.26M · Float 72.95M · 88.7% free float
Institutions13F, as of Jun 30, 2026
291 holders · 103.72M shares · 55 new positions · 155 increased · 82 reduced · 28 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 12.35M | 15.01% | +649.3K | Aug 13, 2026 |
| Baker Bros. Advisors LP | 8.66M | 10.52% | 0 | Aug 14, 2026 |
| Avoro Capital Advisors LLC | 7.47M | 9.09% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 7.11M | 8.65% | +1.05M | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.26M | 7.61% | +792.3K | Aug 14, 2026 |
| BlackRock, Inc. | 5.54M | 6.73% | +477.3K | Aug 7, 2026 |
| BVF Inc/IL | 3.87M | 4.71% | −1.63M | Aug 14, 2026 |
| Wellington Management Group LLP | 3.68M | 4.47% | −214.7K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 14.30% | 11.68M | 13G | May 6, 2026 ↗ |
| Baker Bros. Advisors (GP) LLCincl. Felix J. Baker, Baker Bros. Advisors LP +1 more | 10.90% | 8.68M | 13D | Dec 11, 2025 ↗ |
| T. Rowe Price Associates, Inc. | 7.10% | 5.10M | 13G | Nov 14, 2025 ↗ |
| T. Rowe Price Investment Management, Inc. | 6.70% | 5.46M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.40% | 3.80M | 13G | Jul 17, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | director, 10 percent owner: | 701.3K | 0.85% | Dec 11, 2025 |
| Nello Mainolfi | director, officer: Chief Executive Officer | 666.6K | 0.81% | Jul 7, 2026 |
| Bruce Booth | director | 462.9K | 0.56% | Jul 2, 2026 |
| BVF Partners L P/IL | director, other: See Remarks and Footnotes | 318.9K | 0.39% | Jun 26, 2026 |
| Bruce N. Jacobs | officer: Chief Financial Officer | 244.9K | 0.30% | Jul 2, 2026 |
| Jared Gollob | officer: Chief Medical Officer | 117.1K | 0.14% | Mar 4, 2026 |
| Ellen Chiniara | officer: Chief Legal Officer | 80.1K | 0.10% | Mar 3, 2025 |
| Brian Adams | officer: Chief Legal Officer | 56.6K | 0.07% | Mar 4, 2026 |
| Noah Goodman | officer: Chief Business Officer | 47.2K | 0.06% | Jul 2, 2026 |
| Jeremy G. Chadwick | officer: Chief Operating Officer | 44.0K | 0.05% | May 27, 2026 |
4 ten-percent owners hold 3.89M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 4 people have not refiled in the last 18 months (2.49M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 7, 2026 | Nello Mainolfidirector, officer: Chief Executive Officer | Sale | 50,000 | $119.00 | 666,568 |
| Jun 29, 2026 | Bruce Boothdirector | Sale · 28 lots | 153,300 | $108.05 | 461,794 |
| Jul 1, 2026 | Nello Mainolfidirector, officer: Chief Executive Officer | Sale · 5 lots | 80,000 | $115.29 | 666,568 |
| Jul 1, 2026 | Noah Goodmanofficer: Chief Business Officer | Sale | 3,389 | $114.29 | 47,179 |
| Jun 30, 2026 | Bruce N. Jacobsofficer: Chief Financial Officer | Sale · 8 lots | 77,109 | $114.96 | 244,883 |
| Jun 26, 2026 | Bruce Boothdirector | Sale · 24 lots | 467,878 | $110.29 | 472,267 |
| Jun 26, 2026 | BVF Partners L P/ILdirector, other: See Remarks and Footnotes | Sale · 4 lots | 1,630,658 | $106.50 | 318,910 |
| Jun 25, 2026 | Noah Goodmanofficer: Chief Business Officer | Sale · 2 lots | 5,000 | $114.00 | 50,195 |
| Jun 25, 2026 | Bruce Boothdirector | Sale · 46 lots | 548,321 | $118.76 | 529,718 |
| Jun 24, 2026 | Bruce Boothdirector | Sale · 4 lots | 134,720 | $100.51 | 597,047 |
CongressHouse and Senate disclosures
Not reported.